NeoADAURA is a phase 3 study evaluating the efficacy and safety of neoadjuvant osimertinib alone or in combination with chemotherapy versus chemotherapy alone in patients with stage II-IIIB NSCLC and common EGFR mutations, followed by surgery and adjuvant treatment. Here, EGFR is linked to non-small cell lung carcinoma.